ABC1690

Anti-Wilms Tumor (WT33)

from rabbit, purified by affinity chromatography

• Sinonimo/i: WT33, WT1
• UNSPSC Code: 12352203
• NACRES: NA.41
• eCl@ss: 32160702
• Conjugate: unconjugated
• Clone: polyclonal
• Application: IHC, WB
• Citations: -

Proprietà

• biological source: rabbit
• Quality Segment: 100
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• purified by: affinity chromatography
• species reactivity: human
• species reactivity (predicted by homology): rat (based on 100% sequence homology), mouse (based on 100% sequence homology)
• packaging: antibody small pack of 25 μg
• technique(s): immunohistochemistry: suitable (paraffin), western blot: suitable
• NCBI accession no.: NP_000369.3
• UniProt accession no.: P19544
• target post-translational modification: unmodified
• Gene Information: human ... WT1(7490)

Descrizione

General description

Wilms tumor protein (UniProt: P19544; also known as WT33) is encoded by the WT1 gene (Gene ID: 7490) in human. WT33 serves as a transcription factor that plays an important role in cellular development and cell survival. It is expressed in the kidney and a subset of hematopoietic cells. It regulates the expression of numerous target genes, including EPO. WT33 plays an essential role for development of the urogenital system and has a tumor suppressor as well as an oncogenic role in tumor formation. Eight different isoforms of WT33 have been described that are produced by alternative splicing. Isoforms lacking the KTS motif act as transcription factors while isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA, and can bind RNA. The N-terminal region of WT33 contains a proline-rich region (aa 27-83) involved in transcriptional regulation, self-association, and RNA recognition, while its C-terminal region contains four C2H2-type zinc fingers (aa 323-347, 353-377, 383-405, 414-438) that mediate DNA and RNA binding. The zinc finger domain of WT33 can bind to GC-rich sequences, such as the EGR-1 consensus sequence (5 -GCG(T/G)GGGCG-3 ), the WTE motif (5′-GCGTGGGAGT-3′), or (TCC)n motif. Mutations in WT1 gene are reported to cause Wilms tumors characterized by embryonal malignancy of the kidney. Some mutations are reported to cause nephrotic syndrome 4, which causes severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema.

~59 kDa observed; 49.19 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

Immunogen

KLH-conjugated linear peptide corresponding to 16 amino acids from the N-terminal region of human Wilms Tumor Protein. The immunogen is conserved in isoforms 1,2,3 and 4.

Application

Anti-Wilms Tumor (WT33), Cat. No. ABC1690, is a rabbit polyclonal antibody that detects Wilms tumor protein and has been tested for use in Immunohistochemistry (Paraffin) and Western Blotting.

Research Category
Apoptosis & Cancer

Western Blotting Analysis: 2 µg/mL from a representative lot detected Wilms Tumor (WT33) in human testis tissue lysate.

Immunohistochemistry Analysis: A 1: 250-1,000 dilution from a representative lot detected Wilms Wilms Tumor (WT33) in human testis and human kidney tissues.

Biochem/physiol Actions

This rabbit polyclonal antibody detects Wilms tumor protein in human. It targets an epitope within 16 amino acids from the N-terminal region.

Physical form

Affinity Purified

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Evaluated by Western Blotting in human kidney tissue lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected Wilms Tumor (WT33) in human kidney tissue lysate.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.